Buchumschlag

Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon: drug evaluation

Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor cells (bystander effect). SG showed eff...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Furlanetto, Jenny (VerfasserIn) , Marmé, Frederik (VerfasserIn) , Loibl, Sibylle (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 7 Sep 2022
In: Future oncology
Year: 2022, Jahrgang: 18, Heft: 28, Pages: 3199-3215
ISSN:1744-8301
DOI:10.2217/fon-2022-0407
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2217/fon-2022-0407
Verlag, lizenzpflichtig, Volltext: http://www.futuremedicine.com/doi/10.2217/fon-2022-0407
Volltext
Verfasserangaben:Jenny Furlanetto, Frederik Marmé and Sibylle Loibl
Beschreibung
Zusammenfassung:Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor cells (bystander effect). SG showed efficacy and safety in several epithelial tumors. The phase III ASCENT trial led to the approval of SG (10 mg/kg, d1,8 q3w) in patients with advanced or metastatic triple-negative breast cancer (TNBC) who have received ≥2 prior systemic therapies, including ≥1 for metastatic disease. The phase III TROPiCS-02 trial in heavily pretreated advanced hormone receptor (HR)-positive breast cancer has recently shown an improvement in progression-free survival for patients treated with SG compared to single-agent chemotherapy. The phase III post-neoadjuvant SASCIA study in early high-risk TNBC and HR-positive breast cancer is currently recruiting patients.
Beschreibung:Gesehen am 19.09.2023
Beschreibung:Online Resource
ISSN:1744-8301
DOI:10.2217/fon-2022-0407

Ähnliche Einträge